AstraZeneca PLC
6 December 1999
ASTRAZENECA PHARMACEUTICALS R&D PRESENTATION
LIST OF COMPOUNDS
AstraZeneca R&D Pipeline: NCEs
Cardiovascular
Compound Mechanism Indication Phase Estimated Filing
MAA NDA
ZD4522 Statin Hyperlipidemia III 2Q 2001 2Q
2001
melagatran Thrombin Thrombosis III 2Q 2001 2Q
inhibitor (s.c) 2001
H376/95 Thrombin Thrombosis III 2Q 2001 2Q
inhibitor (oral) 2001
H376/95 Thrombin Prevention of II 4Q 2003 4Q
inhibitor (oral) stroke in AF 2003
AR-C 69931 P2T antagonist TBD II >2002 >2002
(iv)
AR-C 126532 P2T antagonist Arterial I 2005 2005
(oral) thrombosis
H-327/86 Immunomodulator TBD II >2002 >2002
AR-H039242 PPAR agonist Insulin II 2003 2003
resistance
ZD4927 Factor Xa Thrombosis I >2002 >2002
inhibitor
H409/22 NPY antagonist TBD II >2002 >2002
H345/52 Class III TBD II >2002 >2002
antiarrhythmic
(iv)
AR-H 050642 Class III Atrial PC 2005 2005
antiarrhythmic fibrillation
(oral)
Atacand/HTCZ Angiotensin II Hypertension Filed
antagonist/
diuretic
ZD0947 K+ channel opener Urinary I >2002 >2002
incontinence
Gastrointestinal
Esomeprazole Acid pump Acid related GI Filed
magnesium inhibitor disease
mosapride 5HT modulator Dyspepsia II TBD TBD
RAPID Reversible acid Acid related GI I 2004 2004
pump inhibitor disease
rofleponide Topical steroid Inflammatory PC 2004 2004
bowel disease
Helicobacter Vaccine Helicobacter PC 2007 2007
vaccine eradication
Helicobacter Oral treatment Helicobacter PC 2007 2007
project eradication
Oncology
Faslodex Anti-oestrogen Breast III 3Q 2000 3Q
cancer 2000
Iressa Signal Transduction Solid II 4Q 2001 4Q
(ZD1839) Inhibitor (Epidermal tumours 2001
Growth Factor receptor
tyrosine kinase
inhibitor)
ZD0473 3rd generation platin Solid II 2Q 2002 2Q
(iv) tumours 2002
ZD0473 3rd generation platin Solid PC >2002 >2002
(oral) tumours
ZD9331 Thymidilate synthase Solid II 4Q 2001 4Q
inhibitor (iv) tumours 2001
ZD9331 Thymidilate synthase Solid II >2002 3Q
inhibitor (oral) tumours 2002
ZD6126 Vascular targeting agent Solid PC >2002 >2002
tumours
AZD6474 Anti-angiogenic Solid PC >2002 >2002
(Vascular Endothelial tumours
cell Growth Factor
receptor tyrosine kinase
inhibitor)
AstraZeneca R&D Pipeline: NCEs
Respiratory
Compound Mechanism Indicat Phase Estimated Filing
ion MMA NDA
Symbicort Inhaled steroid/B2 Asthma III 4Q 1999 TBD
Turbuhaler agonist
Symbicort Inhaled steroid/B2 COPD III 1Q 2001 TBD
Turbuhaler agonist
ViozanT Dual dopamine/E2 COPD III 3Q 2001 3Q
agonist (pMDI) 2001
Viozan Dual dopamine/E2 COPD III 3Q 2001 3Q
agonist (TBH) 2003
AR-C 89855 Dual dopamine/E2 COPD PC 2005 2005
agonist
RPNS Intranasal steroid Rhinitis II 2004 2004
(rofleponide)
seratrodast Thromboxane inhibitor Asthma III TBD TBD
ZD8321 Human neutrophil ARDS II TBD TBD
elastase inhibitor
ZD0892 Human neutrophil COPD I 2004 2004
elastase inhibitor
AR-D111421 VIP agonist Asthma II TBD TBD
ZD4007 5-lipoxygenase COPD PC 2005 2005
inhibitor
NK1/NK2 Dual neurokinase Asthma PC TBD TBD
antagonist
T3 Dry powder inhaler, Asthma I TBD TBD
non-reservoir
Pain Control
LEF Peripheral II- Acute and II 4Q 2002 4Q
agonist chronic pain 2002
LTA Na channel Analgesia II >2002 >2002
blocker
ZD6416 EP1 antagonist Chronic pain II >2002 >2002
NO-NSAID Nitric oxide Acute and PC >2002 >2002
NSAID chronic pain
derivative
Dental Gel Topical Dental III 2Q 2001 2Q
anaesthesia anaesthesia 2001
Delta Delta opioid Acute and PC
agonist chronic pain
Oral glycine NMDA Antagonist Neuropathic pain PC
CNS
Zendra GABA modulator Stroke III 4Q 2001 1Q 2001
AR-R15896 NMDA Stroke II 3Q 2002 3Q 2002
antagonist
NXY-059 Radical Stroke II 3Q 2002 3Q 2002
scavenger
NAD299 5HT1A Anxiety/Depres II >2002 >2002
antagonist sion
AR-A2 5HT1E Anxiety/Depres PC >2002 >2002
antagonist sion
remacemide NMDA Epilepsy III >2002 >2002
antagonist Parkinson's II >2002 >2002
Disease III 3Q 2001 3Q 2001
Huntington's
chorea
Infection
AZD2563 Oxazolidinone Gram positive PC 4Q 4Q
antibiotic infections, 2003 2003
including multi-
resistant
strains
ME609 (Medivir Antiviral Topical herpes III 2001 2001
joint develop-
ment)
AstraZeneca R&D Pipeline: Line Extensions
Cardiovascular
Compound Mechanism Indication Phase Estimated Filing
MMA NDA
Seloken ZOC/
Toprol XL
Atacand
Zestril
Gastrointestinal
Losec
Entocort
Oncology
Arimidex Aromatase Adjuvant Breast III 4Q 2001 4Q
inhibitor Cancer 2001
Casodex Anti-androgen Early Prostate III 4Q 2002 4Q
Cancer 2002
Tomudex Thymidylate Other tumours II 4Q 2001 -----
synthase &
inhibitor III
Zoladex LHRH agonist Premenopausal III 3Q 2000 3Q
Adjuvant Breast 2000
Cancer
Respiratory
Accolate
Pulmicort
Rhinocort
Oxis
All inhaled products - HFA (non CFC) metered dose inhalers
Pain Control
Naropin
CNS
Seroquel D2/5HT2 Granules 1Q 1Q
antagonist 2001 2001
Seroquel D2/5HT2 Sustained 4Q 4Q
antagonist release 2001 2001
Seroquel D2/5HT2 Mania 4Q 4Q
antagonist 2002 2001
Zomig RapimeltTM Launched 2Q 2000
Zomig Addescents 2Q 4Q
2001 2001
Zomig Nasal spray 2Q 2Q
2000 2000
Infection
Merrem Carbapenem Hospital & III 3Q
antibiotic community 2000
acquired
pneumonia
Merrem Carbapenem Use in III 3Q
antibiotic Neutrapenics 2001
Merrem Carbapenem Cystic III 3Q
antibiotic Fibrosis 2001
Foscavir Antiviral CMV in bone III 2001 2001
marrow
depression
AstraZeneca R&D Pipeline: Discontinued Compounds
Cardiovascular
Compound Mechanism
ZD6169 K+ channel opener
ZD7851/9720 OSC inhibitors
ZD1611/4054 Endothelin A antagonists
Gastrointestinal
ropivacaine gel Inflammatory bowel disease
PTH Osteoporosis
Oncology
ZD2767/9063 Antibody directed enzyme pro-drugs
ZD4190 VTK
ZD9481 Tyrosine kinase inhibitor
ZD0101 Anti-angiogenic
ZD3980 Anti-androgen
Respiratory
RPL(rofleponide) Asthma
TH2 Project Asthma
Mast Cell inhibitor Asthma
ZD1611/4054 Endothelin A antagonists
Pain Control
Chirocaine Local anaesthetic
Cell Therapy (ACTID) Chronic pain
ZD4953/6804 EP1 antagonists
CNS
ATM027 Multiple sclerosis
ZD9379 Glycine antagonist
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.